Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT02919436 |
Other study ID # |
IRB #4742 |
Secondary ID |
|
Status |
Completed |
Phase |
Phase 4
|
First received |
|
Last updated |
|
Start date |
March 2016 |
Est. completion date |
November 2020 |
Study information
Verified date |
January 2022 |
Source |
MaineHealth |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Randomization (1:1) of male patients, over age 50, undergoing elective spine surgery to
tamsulosin versus a placebo.
Description:
Postoperative urinary retention (POUR) is a common complication following certain surgical
operations. While much is known about the innervation and neural regulation of bladder
emptying and storage, the cause of urinary retention after surgery is not fully understood.
Early research has indicated that a small dose of tamsulosin (Flomax®), a commonly used
medication approved to treat urinary symptoms in men with benign prostatic hypertrophy, may
reduce the incidence of POUR. Urinary retention is a prevalent issue in patients undergoing
spinal surgery, leading to patient discomfort and prolonged length of stay. We hypothesize
that the use of perioperative tamsulosin in patients undergoing spinal surgery will decrease
the incidence of POUR.
The study is a prospective, double-blind, randomized, placebo-controlled trial. Subjects will
be randomized 1:1 to receive either oral tamsulosin 0.4 mg or placebo, taken once each
evening, beginning 5 days prior to surgery and continuing through the first postoperative
day. The primary endpoint is met when the patient is able to spontaneously empty their
bladder post-operatively, or needs to be catheterized with either a straight or indwelling
urinary catheter for post-operative urinary retention, whichever occurs first.